Eledon Pharmaceuticals Presents Long-Term Phase 2 BESTOW Data Showing Tegoprubart Benefits Over Tacrolimus in Kidney Transplant
Eledon Pharmaceuticals reported positive long-term Phase 2 BESTOW trial results for tegoprubart in kidney transplant, showing sustained kidney function benefits and improved patient outcomes versus tacrolimus. The company outlined plans for a Phase 3 registrational trial and seeks an FDA meeting in early 2027. Safety data indicated lower adverse event rates with tegoprubart.